Webinar: PARP Inhibitors: What You Need to Know

October 18, 2017 7:32 pm

Join OCRFA on Monday, Oct. 23rd at 6:00pm ET for a webinar on PARP Inhibitors with Dr. Ursula Matulonis of Dana-Farber Cancer Institute.

There is a great amount of excitement in the ovarian cancer clinical and research communities about the … Read more

Another Win for PARP Inhibition in Ovarian Cancer

September 12, 2017 4:09 pm

Women with recurrent, platinum-sensitive ovarian cancer lived twice as long without disease progression when they received maintenance therapy with the PARP inhibitor rucaparib (Rubraca), a randomized trial showed.

Overall, patients treated with rucaparib had a median progression-free survival of 10.8 … Read more

PARP Inhibitors Changing the Landscape of Ovarian Cancer Treatment

July 11, 2017 5:53 pm

With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more

Pairing PARP Inhibitors With Other Drug Types the Next Frontier for BRCA-Mutated Ovarian Cancers

June 13, 2017 6:35 pm

The idea of interfering with DNA’s self-repair capabilities has been at the heart of this decade’s progress in treating ovarian cancer, and combining the PARP inhibitors that accomplish that with other types of therapies will be the focus of treatment … Read more

Ovarian Cancer Patients Actively Seeking PARP Inhibitor Therapy, Expert Says

May 15, 2017 5:19 pm

In the treatment of advanced ovarian cancer, PARP inhibitors, including olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula), are stealing the limelight, explains Dennis Scribner, MD.

In an interview with Targeted Oncology, Scribner, a gynecologic oncologist at Arizona Oncology, discussed … Read more

Ending a Dry Spell of Years Without Treatment for Ovarian Cancer

May 3, 2017 7:04 pm

Teri Woodhull is decidedly proactive. A strong family history of breast cancer led her to undergo a preventive bilateral mastectomy at age 30. Seventeen years later, she was diagnosed with stage 3b high-grade serous epithelial ovarian cancer.

“I do have … Read more

PARP Inhibitor Approvals Offer Ovarian Cancer Patients New Hope

April 18, 2017 5:20 pm

The ovarian cancer treatment paradigm underwent another transformation near the end of 2016 with the FDA approval of the PARP inhibitor rucaparib (Rubraca) for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of … Read more

PARP Inhibitor Active in BRCA Subgroups

March 14, 2017 5:52 pm

Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.

Results showed a median PFS of … Read more

Tesaro Opens Expanded Program of PARP inhibitor for U.S. Ovarian Cancer Patients

January 18, 2017 7:31 pm

Tesaro has opened an expanded access program (EAP) in the United States for their investigational poly ADP ribose polymerase (PARP) inhibitor, niraparib.
Now, niraparib is can be available, to treat a patient who meet certain criteria, with a serious disease … Read more

PARP Inhibitor Shows Benefit in Ovarian Cancer

November 28, 2016 8:01 pm

Lynparza (olaparib) demonstrated improved progression-free survival (PFS) compared to the placebo arm for patients with ovarian cancer, according to findings from the phase 3 SOLO-2 trial. The single-agent PARP inhibitor was tested in the maintenance setting for patients with advanced … Read more